CORT
Corcept Therapeutics IncorporatedNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.00B
P/E Ratio
56.82
EPS
$0.82
Beta
0.25
52W High
$91.00
52W Low
$28.66
50-Day MA
$38.84
200-Day MA
$60.93
Dividend Yield
—
Profit Margin
13.10%
Forward P/E
131.58
PEG Ratio
0.81
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Fundamentals
| Revenue (TTM) | $761.41M |
| Gross Profit (TTM) | $748.43M |
| EBITDA | $45.95M |
| Operating Margin | 2.22% |
| Return on Equity | 15.00% |
| Return on Assets | 3.34% |
| Revenue/Share (TTM) | $7.33 |
| Book Value | $6.11 |
| Price-to-Book | 7.73 |
| Price-to-Sales (TTM) | 6.57 |
| EV/Revenue | 6.09 |
| EV/EBITDA | 99.36 |
| Quarterly Earnings Growth (YoY) | -21.60% |
| Quarterly Revenue Growth (YoY) | 11.10% |
| Shares Outstanding | $107.36M |
| Float | $88.05M |
| % Insiders | 11.54% |
| % Institutions | 71.87% |
Historical Volatility
HV 10-Day
38.95%
HV 20-Day
36.08%
HV 30-Day
64.27%
HV 60-Day
63.33%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($67.40 target)
1
Strong Buy3
Buy2
HoldData last updated: 4/30/2026